State of Wisconsin Investment Board lessened its position in Amgen, Inc. (NASDAQ:AMGN) by 16.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 712,661 shares of the medical research company’s stock after selling 136,616 shares during the period. State of Wisconsin Investment Board’s holdings in Amgen were worth $123,932,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of AMGN. Baker Ellis Asset Management LLC purchased a new position in shares of Amgen during the third quarter valued at approximately $108,000. Phocas Financial Corp. purchased a new position in shares of Amgen during the second quarter valued at approximately $110,000. Horan Capital Advisors LLC. purchased a new position in shares of Amgen during the third quarter valued at approximately $150,000. Salem Investment Counselors Inc. raised its holdings in shares of Amgen by 4.7% during the second quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock valued at $139,000 after purchasing an additional 36 shares during the last quarter. Finally, Atlantic Trust LLC purchased a new position in shares of Amgen during the second quarter valued at approximately $146,000. Hedge funds and other institutional investors own 79.53% of the company’s stock.
Shares of NASDAQ AMGN opened at $170.48 on Monday. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. The firm has a market capitalization of $122,841.44, a PE ratio of 13.55, a PEG ratio of 2.09 and a beta of 1.36. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23.
Amgen declared that its Board of Directors has authorized a share buyback program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.10%. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
In other news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 4,575 shares of company stock valued at $838,064. Corporate insiders own 0.19% of the company’s stock.
AMGN has been the subject of several research reports. Morgan Stanley decreased their price objective on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a report on Friday, February 2nd. Vetr raised shares of Amgen from a “sell” rating to a “hold” rating and set a $181.60 price objective for the company in a report on Tuesday, February 27th. Oppenheimer reissued a “buy” rating and set a $205.00 price objective on shares of Amgen in a report on Tuesday, January 30th. Piper Jaffray reissued a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Finally, Goldman Sachs cut shares of Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company’s stock. Amgen has a consensus rating of “Hold” and a consensus target price of $191.26.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.